Neuropathology of dementia

The Behavioral Neurology of Dementia

Volumn , Issue , 2009, Pages 142-160

  Macedo, Marcelo N ^a   Kim, Eun Joo ^b   Seeley, William W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Pusan National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78649232616     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511581410.011     Document Type: Chapter

References (160)

1. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003;60 (8):1119-22.
2. Bachman DL, Wolf PA, Linn RT et al. Incidence of dementia and probable Alzheimer’s disease in a general population: the Framingham Study. Neurology 1993;43 (3 Pt 1):515-19.
3. Knopman DS, Boeve BF, Parisi JE et al. Antemortem diagnosis of frontotemporal lobar degeneration. Ann Neurol 2005;57(4):480-8.
4. Forman MS, Farmer J, Johnson JK et al. Frontotemporal dementia: clinicopathological correlations. Ann Neurol 2006;59(6):952-62.
5. Brun A, Gustafson L. Limbic lobe involvement in presenile dementia. Arch Psychiatr Nervenkr 1978;226 (2):79-93.
6. Brun A, Liu X, Erikson C. Synapse loss and gliosis in the molecular layer of the cerebral cortex in Alzheimer’s disease and in frontal lobe degeneration. Neurodegeneration 1995;4(2):171-7.
7. Mesulam MM. Large-scale neurocognitive networks and distributed processing for attention, language, and memory. Ann Neurol 1990;28(5):597-613.
8. Ritchie K, Lovestone S. The dementias. Lancet 2002;360 (9347):1759-66.
9. Kukull WA, Higdon R, Bowen JD et al. Dementia and Alzheimer disease incidence: a prospective cohort study. Arch Neurol 2002;59(11):1737-46.
10. Braak H, Braak E. Staging of Alzheimer’s disease-related neurofibrillary changes. Neurobiol Aging 1995;16 (3):271-284.
11. Hyman BT, Damasio AR. Hierarchical vulnerability of the entorhinal cortex and the hippocampal formation to Alzheimer neuropathological changes: a semiquantitative study. Neurology 1990;40:403.
12. Hyman BT, Damasio AR, Van Hoesen GW, Barnes CL. Alzheimer’s disease: cell-specific pathology isolates the hippocampal formation. Science 1984;298:83-95.
13. Reiman EM, Caselli RJ, Yun LS, Chen K et al. Preclinical evidence of Alzheimer’s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996;334(12):752-8.
14. Gorno-Tempini ML, Dronkers NF, Rankin KP et al. Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol 2004;55(3):335-46.
15. Galton CJ, Patterson K, Xuereb JH, Hodges JR. Atypical and typical presentations of Alzheimer’s disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases. Brain 2000;123 Pt 3:484-98.
16. Zakzanis KK, Boulos MI. Posterior cortical atrophy. Neurologist 2001;7(6):341-9.
17. Johnson J, Head E, Kim R et al. Clinical and pathological evidence for a frontal variant of Alzheimer disease. Arch Neurol 1999;56(10):1233-9.
18. Brun A, Gustafson L. Distribution of cerebral degeneration in Alzheimer’s disease. A clinicopathological study. Arch Psychiatr Nervenkr 1976;223 (1):15-33.
19. Alzheimer A. Uber einen eigenartigen, schweren Erkrankungsprozess der Hirnrinde. Neurol Zbl 1906;25:1134.
20. Dickson DW. The pathogenesis of senile plaques. J Neuropathol Exp Neurol 1997;56(4):321-39.
21. Goedert M. Tau protein and the neurofibrillary pathology of Alzheimer’s disease. Trends Neurosci 1993;16(11):460-5.
22. Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients in Alzheimer’s disease. Cerebral Cortex 1991;1(1):103-16.
23. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology 1992;42(3 Pt 1):631-9.
24. Ball MJ. Neuronal loss, neurofibrillary tangles and granulovacuolar degeneration in the hippocampus with ageing and dementia. A quantitative study. Acta Neuropathol (Berl) 1977;37(2):111-8.
25. Vinters HV. Cerebral amyloid angiopathy. A critical review. Stroke 1987;18(2):311-24.
26. Gibson PH, Tomlinson BE. Numbers of Hirano bodies in the hippocampus of normal and demented people with Alzheimer’s disease. J Neurol Sci 1977;33 (1-2):199-206.
27. Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol 1989;24 (3):173-82.
28. Mirra S, Heyman A, McKeel D et al. The consortium to establish a registry for Alzheimer’s disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 1991; 41(4):479-486.
29. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82(4):239-59.
30. Hyman BT, Trojanowski JQ. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol 1997; 56(10):1095-7.
31. Bigio EH, Hynan LS, Sontag E, Satumtira S, White CL. Synapse loss is greater in presenile than senile onset Alzheimer disease: implications for the cognitive reserve hypothesis. Neuropathol Appl Neurobiol 2002;28 (3):218-27.
32. Marshall GA, Fairbanks LA, Tekin S, Vinters HV, Cummings JL. Early-onset Alzheimer’s disease is associated with greater pathologic burden. J Geriatr Psychiatry Neurol 2007;20(1):29-33.
33. Kim EJ, Cho SS, Jeong Y et al. Glucose metabolism in early onset versus late onset Alzheimer’s disease: an SPM analysis of 120 patients. Brain 2005;128 (Pt 8):1790-801.
34. Frisoni GB, Pievani M, Testa C et al. The topography of grey matter involvement in early and late onset Alzheimer’s disease. Brain 2007;130(Pt 3):720-30.
35. Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science 1992;256(5054):184-5.
36. Goedert M, Spillantini MG, Cairns NJ, Crowther RA. Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron 1992;8(1):159-68.
37. Farrer LA, Myers RH, Cupples LA et al. Transmission and age-at-onset patterns in familial Alzheimer’s disease: evidence for heterogeneity. Neurology 1990;40 (3 Pt 1):395-403.
38. St George-Hyslop PH, Tanzi RE, Polinsky RJ. The Genetic Defect Causing Familial Alzheimer’s Disease Maps on Chromosome 21. Science 1987;235:885-90.
39. Schellenberg GD, Bird TD, Wijsman EM et al. Genetic linkage evidence for a familial Alzheimer’s disease locus on chromosome 14. Science 1992;258:68-671.
40. Levy-Lahad E, Wasco W, Poorkaj P et al. Candidate gene for the chromosome 1 familial Alzheimer’s disease locus. Science 1995;269(5226):973-7.
41. Schmitt FA, Davis DG, Wekstein DR et al. “Preclinical” AD revisited: neuropathology of cognitively normal older adults. Neurology 2000;55(3):370-6.
42. Ratnavalli E, Brayne C, Dawson K, Hodges JR. The prevalence of frontotemporal dementia. Neurology 2002;58(11):1615-21.
43. Knopman DS, Petersen RC, Edland SD, Cha RH, Rocca WA. The incidence of frontotemporal lobar degeneration in Rochester, Minnesota, 1990 through 1994. Neurology 2004;62(3):506-8.
44. Neary D, Snowden JS, Gustafson L et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51(6): 1546-54.
45. Schroeter ML, Raczka K, Neumann J, von Cramon DY. Neural networks in frontotemporal dementia: a meta-analysis. Neurobiol Aging 2006;29(3):418-26.
46. Seeley WW, Crawford R, Rascovsky K et al. Frontal paralimbic network atrophy in very mild behavioral variant frontotemporal dementia. Arch Neurol 2008;65(2):249-55.
47. Perry RJ, Graham A, Williams G et al. Patterns of frontal lobe atrophy in frontotemporal dementia: a volumetric MRI study. Dement Geriatr Cogn Disord 2006;22(4):278-87.
48. Broe M, Hodges JR, Schofield E et al. Staging disease severity in pathologically confirmed cases of fronto temporal dementia. Neurology 2003;60(6):1005-11.
49. Hodges JR, Patterson K, Oxbury S, Funnell E. Semantic dementia. Progressive fluent aphasia with temporal lobe atrophy. Brain 1992;115 (Pt 6):1783-806.
50. Snowden J. Semantic dementia. 2nd edition ed. New York: Oxford University Press; 2000.
51. Seeley WW, Bauer AM, Miller BL et al. The natural history of temporal variant frontotemporal dementia. Neurology 2005;64(8):1384-90.
52. Thompson SA, Patterson K, Hodges JR. Left/right asymmetry of atrophy in semantic dementia: behavioral-cognitive implications. Neurology 2003;61(9):1196-203.
53. Neary D, Snowden JS, Mann DM et al. Frontal lobe dementia and motor neuron disease. J Neurol Neurosurg Psychiatry 1990;53(1):23-32.
54. Munoz DG, Dickson DW, Bergeron C et al. The neuropathology and biochemistry of frontotemporal dementia. Ann Neurol 2003;54(Suppl 5):S24-8.
55. Mackenzie IR, Neumann M, Bigio EH et al. Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol 2009;117(1):15-8.
56. Forman MS, Lee VM, Trojanowski JQ. New insights into genetic and molecular mechanisms of brain degeneration in tauopathies. J Chem Neuroanat 2000;20 (3-4):225-44.
57. Bigio EH, Lipton AM, Yen SH et al. Frontal lobe dementia with novel tauopathy: sporadic multiple system tauopathy with dementia. J Neuropathol Exp Neurol 2001;60(4):328-41.
58. Dickson DW. Pick’s disease: a modern approach. Brain Pathol 1998;8(2):339-54.
59. Probst A, Tolnay M, Langui D, Goedert M, Spillantini MG. Pick’s disease: hyperphosphorylated tau protein segregates to the somatoaxonal compartment. Acta Neuropathol (Berl) 1996;92(6):588-96.
60. Feany MB, Mattiace LA, Dickson DW. Neuropathologic overlap of progressive supranuclear palsy, Pick’s disease and corticobasal degeneration. J Neuropathol Exp Neurol 1996;55(1):53-67.
61. Wilhelmsen K, Lynch T, Pavlou E et al. Localization of disinhibition-dementia-parkinsonism-amyotrophy complex to 17q21-22. Am J Hum Genet 1994;6:1159-65.
62. Hutton M, Lendon CL, Rizzu P et al. Association of missense and 5’-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998;393 (6686):702-5.
63. Foster NL, Wilhelmsen K, Sima AA et al. Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Conference Participants. Annals of Neurology 1997;41(6):706-15.
64. Bird TD, Wijsman EM, Nochlin D et al. Chromosome 17 and hereditary dementia: linkage studies in three non-Alzheimer families and kindreds with late-onset FAD. Neurology 1997;48(4):949-54.
65. Heutink P, Stevens M, Rizzu P et al. Hereditary frontotemporal dementia is linked to chromosome 17q21-q22: a genetic and clinicopathological study of three Dutch families. Ann Neurol 1997;41(2):150-9.
66. Lipton AM, White CL, 3rd, Bigio EH. Frontotemporal lobar degeneration with motor neuron disease-type inclusions predominates in 76 cases of frontotemporal degeneration. Acta Neuropathol (Berl) 2004;108 (5):379-85.
67. Mackenzie IR, Baborie A, Pickering-Brown S et al. Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: classification and relation to clinical phenotype. Acta Neuropathol 2006;112(5):539-49.
68. Sampathu DM, Neumann M, Kwong LK et al. Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. Am J Pathol 2006; 169(4):1343-52.
69. Mackenzie IR, Baker M, Pickering-Brown S et al. The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene. Brain 2006;129(Pt 11):3081-90.
70. Jackson M, Lennox G, Lowe J. Motor neurone disease- inclusion dementia. Neurodegeneration 1996; 5(4):339-50.
71. Sreedharan J, Blair IP, Tripathi VB et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008;319(5870):1668-72.
72. Cairns NJ, Grossman M, Arnold SE et al. Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease. Neurology 2004;63(8): 1376-84.
73. Neumann M, Sampathu DM, Kwong LK et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006;314(5796):130-3.
74. Cairns NJ, Zhukareva V, Uryu K et al. alpha-internexin is present in the pathological inclusions of neuronal intermediate filament inclusion disease. Am J Pathol 2004;164(6):2153-61.
75. Josephs KA, Uchikado H, McComb RD et al. Extending the clinicopathological spectrum of neurofilament inclusion disease. Acta Neuropathol (Berl) 2005;109 (4):427-32.
76. Knopman DS, Mastri AR, Frey WHD et al. Dementia lacking distinctive histologic features: a common non-Alzheimer degenerative dementia. Neurology 1990;40(2):251-6.
77. Josephs KA, Jones AG, Dickson DW. Hippocampal sclerosis and ubiquitin-positive inclusions in dementia lacking distinctive histopathology. Dement Geriatr Cogn Disord 2004;17(4):342-5.
78. Holm IE, Englund E, Mackenzie IR et al. A reassessment of the neuropathology of frontotemporal dementia linked to chromosome 3. J Neuropathol Exp Neurol 2007;66(10):884-91.
79. Mackenzie IR, Foti D, Woulfe J, Hurwitz TA. Atypical frontotemporal lobar degeneration with ubiquitinpositive, TDP-43-negative neuronal inclusions. Brain 2008;131(Pt 5):1282-93.
80. Josephs KA, Lin WL, Ahmed Z et al. Frontotemporal lobar degeneration with ubiquitin-positive, but TDP-43-negative inclusions. Acta Neuropathol 2008;116(2):159-67.
81. Baker M, Mackenzie IR, Pickering-Brown SM et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006;442:916-19.
82. Cruts M, Gijselinck I, van der Zee J et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 2006;442:920-4.
83. Mukherjee O, Pastor P, Cairns NJ et al. HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin-positive, tau-negative inclusions caused by a missense mutation in the signal peptide of progranulin. Ann Neurol 2006;60(3):314-22.
84. Schymick JC, Yang Y, Andersen PM et al. Progranulin mutations and amyotrophic lateral sclerosis or amyotrophic lateral sclerosis-frontotemporal dementia phenotypes. J Neurol Neurosurg Psychiatry 2007;78 (7):754-6.
85. Gass J, Cannon A, Mackenzie IR et al. Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet 2006;15(20):2988-3001.
86. Seeley WW, Carlin DA, Allman JM et al. Early frontotemporal dementia targets neurons unique to apes and humans. Ann Neurol 2006;60(6):660-7.
87. Seeley WW, Menon V, Schatzberg AF et al. Dissociable intrinsic connectivity networks for salience processing and executive control. J Neurosci 2007;27(9):2349-56.
88. Hof PR, Van Der Gucht E. Structure of the cerebral cortex of the humpback whale, Megaptera novaeangliae (Cetacea, Mysticeti, Balaenopteridae). Anat Rec A Discov Mol Cell Evol Biol 2006.
89. Hakeem AY, Sherwood CC, Bonar CJ et al. Von Economo neurons in the elephant brain. Anat Rec (Hoboken) 2009;292(2):242-8.
90. Hodges JR, Davies RR, Xuereb JH et al. Clinicopathological correlates in frontotemporal dementia. Ann Neurol 2004;56(3):399-406.
91. Knibb JA, Xuereb JH, Patterson K, Hodges JR. Clinical and pathological characterization of progressive aphasia. Ann Neurol 2006;59(1):156-65.
92. Davies RR, Hodges JR, Kril JJ et al. The pathological basis of semantic dementia. Brain 2005;128(Pt 9): 1984-95.
93. Josephs KA, Duffy JR, Strand EA et al. Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain 2006;129(Pt 6):1385-98.
94. Gorno-Tempini ML, Murray RC, Rankin KP et al. Clinical, cognitive and anatomical evolution from nonfluent progressive aphasia to corticobasal syndrome: a case report. Neurocase 2004;10(6):426-36.
95. Mahapatra RK, Edwards MJ, Schott JM, Bhatia KP. Corticobasal degeneration. Lancet Neurol 2004;3 (12):736-43.
96. Rinne JO, Lee MS, Thompson PD, Marsden CD. Corticobasal degeneration. A clinical study of 36 cases. Brain 1994;117 (Pt 5):1183-96.
97. Wenning GK, Litvan I, Jankovic J et al. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry 1998;64(2):184-9.
98. Riley DE, Lang AE. Clinical diagnostic criteria. Adv Neurol 2000;82:29-34.
99. Graham NL, Bak TH, Hodges JR. Corticobasal degeneration as a cognitive disorder. Mov Disord 2003;18(11):1224-32.
100. Kompoliti K, Goetz CG, Boeve BF et al. Clinical presentation and pharmacological therapy in corticobasal degeneration. Arch Neurol 1998;55 (7):957-61.
101. Grimes DA, Lang AE, Bergeron CB. Dementia as the most common presentation of cortical-basal ganglionic degeneration. Neurology 1999;53(9): 1969-74.
102. Murray R, Neumann M, Forman MS et al. Cognitive and motor assessment in autopsy-proven corticobasal degeneration. Neurology 2007;68(16):1274-83.
103. Feany MB, Dickson DW. Widespread cytoskeletal pathology characterizes corticobasal degeneration. Am J Pathol 1995;146(6):1388-96.
104. Litvan I, Agid Y, Calne D et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47(1):1-9.
105. Nath U, Ben-Shlomo Y, Thomson RG et al. The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. Brain 2001;124(Pt 7):1438-49.
106. Lantos PL. The neuropathology of progressive supranuclear palsy. J Neural Transm Suppl 1994;42:137-52.
107. Komori T, Arai N, Oda M et al. Astrocytic plaques and tufts of abnormal fibers do not coexist in corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol (Berl) 1998;96(4):401-8.
108. Pillon B, Blin J, Vidailhet M et al. The neuropsychological pattern of corticobasal degeneration: comparison with progressive supranuclear palsy and Alzheimer’s disease. Neurology 1995;45(8):1477-83.
109. Spillantini MG, Goedert M. Tau mutations in familial frontotemporal dementia. Brain 2000;123(Pt 5):857-9.
110. Houlden H, Baker M, Morris HR et al. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology 2001;56 (12):1702-6.
111. Lang AE, Bergeron, C. Corticobasal degeneration and PSP: the same disease? Mov Disord 2002;17:1404-5.
112. Nasreddine ZS, Loginov M, Clark LN et al. From genotype to phenotype: a clinical pathological, and biochemical investigation of frontotemporal dementia and parkinsonism (FTDP-17) caused by the P301L tau mutation. Ann Neurol 1999;45(6):704-15.
113. McKeith I, Galasko D, Kosaka K et al. Consensus guidleines for the clinical and pathologic diagnosis of dementia with Lewy Bodies. Neurology 1996;47:1113-24.
114. Holmes C, Cairns N, Lantos P, Mann A. Validity of current clinical criteria for Alzheimer’s disease, vascular dementia, and dementia with Lewy bodies. Br J Psychiatry 1999;174:45-51.
115. Lim A, Tsuang D, Kukull W et al. Cliniconeuropathological correlation of Alzheimer’s disease in a community-based case series. J Am Geriatr Soc 1999;47(5):564-9.
116. Ransmayr G. Dementia with Lewy bodies: prevalence, clinical spectrum and natural history. J Neural Transm Suppl 2000(60):303-14.
117. McKeith IG, Dickson DW, Lowe J et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65 (12):1863-72.
118. Double KL, Halliday GM, McRitchie DA et al. Regional brain atrophy in idiopathic parkinson’s disease and diffuse Lewy body disease. Dementia 1996;7(6):304-13.
119. Perry RH, Irving D, Blessed G, Fairbairn A, Perry EK. Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly. J Neurol Sci 1990;95:119-139.
120. Rezaie P, Cairns NJ, Chadwick A, Lantos PL. Lewy bodies are located preferentially in limbic areas in diffuse Lewy body disease. Neurosci Lett 1996;212 (2):111-4.
121. Gomez-Tortosa E, Newell K, Irizarry MC et al. Clinical and quantitative pathologic correlates of dementia with Lewy bodies. Neurology 1999;53(6):1284-91.
122. Giasson B, Lee, M-YV, Trojanowski, JQ. Parkinson’s disease, dementia with lewy bodies, multiple system atrophy and the spectrum of disease with alpha synuclein inclusions. 2nd edn. New York: Cambridge University Press; 2004.
123. Dickson DW, Ruan D, Crystal H et al. Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer’s disease: light and electron microscopic immunocytochemistry of CA2-3 neurites specific to DLBD. Neurology 1991;41(9):1402-9.
124. Dickson D, Schmidt M, Lee V et al. Immunoreactivity profile of hippocampal Ca2/3 neurites in diffuse Lewy body disease. Acta Neuropathologica 1994;87:269-276.
125. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with lewy bodies. Proc Natl Acad Sci USA 1998;95 (11):6469-73.
126. Kosaka K. Diffuse Lewy body disease. Neuropathology 2000;20(Suppl):S73-8.
127. Merdes AR, Hansen LA, Jeste DV et al. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology 2003;60 (10):1586-90.
128. Del Ser T, Hachinski V, Merskey H, Munoz DG. Clinical and pathologic features of two groups of patients with dementia with Lewy bodies: effect of coexisting Alzheimer-type lesion load. Alzheimer Dis Assoc Disord 2001;15(1):31-44.
129. Lopez OL, Becker JT, Kaufer DI et al. Research evaluation and prospective diagnosis of dementia with Lewy bodies. Arch Neurol 2002;59(1):43-6.
130. Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 1999;354 (9192):1771-5.
131. Wenning GK, Colosimo C, Geser F, Poewe W. Multiple system atrophy. Lancet Neurol 2004;3 (2):93-103.
132. Wenning GK, Tison F, Ben Shlomo Y, Daniel SE, Quinn NP. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord 1997;12 (2):133-47.
133. Gilman S, Low PA, Quinn N et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 1999;163(1):94-8.
134. Robbins TW, James M, Owen AM et al. Cognitive deficits in progressive supranuclear palsy, Parkinson’s disease, and multiple system atrophy in tests sensitive to frontal lobe dysfunction. J Neurol Neurosurg Psychiatry 1994;57(1):79-88.
135. Meco G, Gasparini M, Doricchi F. Attentional functions in multiple system atrophy and Parkinson’s disease. J Neurol Neurosurg Psychiatry 1996;60(4):393-8.
136. Burk K, Daum I, Rub U. Cognitive function in multiple system atrophy of the cerebellar type. Mov Disord 2006;21(6):772-6.
137. Sato K, Kaji R, Matsumoto S, Goto S. Cell type-specific neuronal loss in the putamen of patients with multiple system atrophy. Mov Disord 2007;22(5):738-42.
138. Wenning GK, Tison F, Elliott L, Quinn NP, Daniel SE. Olivopontocerebellar pathology in multiple system atrophy. Mov Disord 1996;11(2):157-62.
139. Gai WP, Power JH, Blumbergs PC, Blessing WW. Multiple-system atrophy: a new alpha-synuclein disease? Lancet 1998;352(9127):547-8.
140. Tu PH, Galvin JE, Baba M, Giasson B et al. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol 1998;44(3):415-22.
141. Lantos PL. The definition of multiple system atrophy: a review of recent developments. J Neuropathol Exp Neurol 1998;57(12):1099-111.
142. Duda JE, Giasson BI, Gur TL et al. Immunohistochemical and biochemical studies demonstrate a distinct profile of alpha-synuclein permutations in multiple system atrophy. J Neuropathol Exp Neurol 2000;59(9):830-41.
143. Lin WL, DeLucia MW, Dickson DW. Alpha-synuclein immunoreactivity in neuronal nuclear inclusions and neurites in multiple system atrophy. Neurosci Lett 2004;354(2):99-102.
144. Polymeropoulos M, Lavedan C, Leroy E et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s diseae. Science 1997;276:2045-8.
145. Soma H, Yabe I, Takei A et al. Heredity in multiple system atrophy. J Neurol Sci 2006;240(1-2):107-10.
146. Hara K, Momose Y, Tokiguchi S et al. Multiplex families with multiple system atrophy. Arch Neurol 2007;64(4):545-51.
147. Folstein S. Huntington’s Disease: A Disorder of Families. Baltimore: Johns Hopkins University Press; 1989.
148. Feigin A, Kieburtz K, Bordwell K et al. Functional decline in Huntington’s disease. Mov Disord 1995; 10(2):211-4.
149. Zakzanis KK. The subcortical dementia of Huntington’s disease. J Clin Exp Neuropsychol 1998; 20(4):565-78.
150. Mendez MF. Huntington’s disease: update and review of neuropsychiatric aspects. Int J Psychiatry Med 1994;24(3):189-208.
151. Berrios GE, Wagle AC, Markova IS et al. Psychiatric symptoms in neurologically asymptomatic Huntington’s disease gene carriers: a comparison with gene negative at risk subjects. Acta Psychiatr Scand 2002;105(3):224-30.
152. Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol 1998;57(5):369-84.
153. Graveland GA, Williams RS, DiFiglia M. Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington’s disease. Science 1985;227(4688):770-3.
154. Vonsattel J-P, Myers RH, Stevens TJ et al. Neuropathological classification of Huntington’s disease. J Neuropath Exp Neurology 1985;44:559-77.
155. The Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 1993;72:971-83.
156. Brandt J, Bylsma FW, Gross R et al. Trinucleotide repeat length and clinical progression in Huntington’s disease. Neurology 1996;46(2):527-31.
157. Persichetti F, Srinidhi J, Kanaley L et al. Huntington’s disease CAG trinucleotide repeats in pathologically confirmed post-mortem brains. Neurobiol Dis 1994;1(3):159-66.
158. Busch A, Engemann S, Lurz R et al. Mutant huntingtin promotes the fibrillogenesis of wild-type huntingtin: a potential mechanism for loss of huntingtin function in Huntington’s disease. J Biol Chem 2003;278 (42):41452-61.
159. Zuccato C, Liber D, Ramos C et al. Progressive loss of BDNF in a mouse model of Huntington’s disease and rescue by BDNF delivery. Pharmacol Res 2005;52 (2):133-9.
160. Mackenzie IR, Bigio EH, Ince PG et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 2007;61(5):427-34.